Today, we are excited to announce that the Falcon 180B foundation model developed by Technology Innovation Institute (TII) is available for customers through Amazon SageMaker JumpStart to deploy with one-click for running inference. With a 180-billion-parameter size and trained on a massive 3.5-trillion-token dataset, Falcon 180B is the largest and one of the most performant models with openly accessible weights. You can try out this model with SageMaker JumpStart, a machine learning (ML) hub that provides access to algorithms, models, and ML solutions so you can quickly get started with ML. In this post, we walk through how to discover and deploy the Falcon 180B model via SageMaker JumpStart.
Amazon SageMaker Domain in VPC only mode to support SageMaker Studio with auto shutdown Lifecycle Configuration and SageMaker Canvas with Terraform
Amazon SageMaker Domain supports SageMaker machine learning (ML) environments, including SageMaker Studio and SageMaker Canvas. SageMaker Studio is a fully integrated development environment (IDE) that provides a single web-based visual interface where you can access purpose-built tools to perform all ML development steps, from preparing data to building, training, and deploying your ML models, improving
Mayfair Gold (TSXV:MFG) Reports Drill Results from Footwall Zone in Fenn-Gib Project, Northeast Ontario
Mayfair Gold (TSXV:MFG) has reported new drill results from its higher-grade Footwall Zone, which is situated roughly 100 meters north of the Fenn-Gib gold deposit. The Fenn-Gib Project, under Mayfair’s full control, is located in the Timmins region of Northeast Ontario. This project houses an open-pit-constrained Indicated mineral resource, which estimates 3.38 million ounces of
The post Mayfair Gold (TSXV:MFG) Reports Drill Results from Footwall Zone in Fenn-Gib Project, Northeast Ontario appeared first on MiningFeeds.
Glasgow diagnostics spinout Microplate Dx has closed a £2.5m seed funding round to develop its point-of-care diagnostic platform which can confirm the presence of bacteria and guide a patient’s doctor
Mendus, a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the company’s lead program, vididencel, for